Founded in ‘Aiea, Hawaii Biotech, Inc. is a biotechnology company dedicated to the research and development of prophylactic vaccines for infectious diseases. The company's core mission is to combat emerging and re-emerging infectious diseases through innovative vaccine solutions. Their product offerings include small molecule drug candidates for treating Anthrax intoxication and botulism, as well as a pipeline of recombinant subunit protein vaccines developed using their stable insect cell vaccine platform.

Hawaii Biotech has garnered attention for its advanced protein production platform, which enhances the stability and efficacy of its vaccine candidates. The company has attracted notable investors and collaborators in the biotech industry, contributing to its progress and credibility. Key achievements include the development of promising vaccine candidates and drug treatments that address critical public health threats. Overall, Hawaii Biotech's impact lies in its potential to significantly improve global health outcomes through cutting-edge vaccine technology.